切除不能な肝がん患者の治療における高線量外照射療法後の改変免疫細胞(自家樹状細胞)とワクチン(Prevnar)
切除不能な肝癌患者における高線量原体外照射放射線療法後の樹状細胞の腫瘍内注射に関するパイロット研究
This early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in combination with immune checkpoint inhibition (with bevacizumab and atezolizumab or druvalumab) in treating patients liver cancer that cannot be removed by surgery (unresectable) after undergoing standard high-dose external beam radiotherapy. Autologous dendritic cells are immune cells generated from patients' own white blood cells that are grown in a special lab and trained to stimulate the immune system to destroy tumor cells. A pneumonia vaccine called Prevnar may also help stimulate the immune system. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab and durvalumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving autologous dendritic cells and Prevnar in combination with immune checkpoint inhibition after radiotherapy may be safe, and tolerable and may stimulate the body's own immune system to fight against the tumor in patients with unresectable liver cancer.
調査の概要
状態
条件
介入・治療
- 生物学的:Bevacizumab
- 手順:Magnetic Resonance Imaging
- 手順:Biopsy Procedure
- 手順:Computed Tomography
- 手順:Positron Emission Tomography
- 生物学的:Atezolizumab
- 生物学的:Durvalumab
- 手順:Biospecimen Collection
- 放射線:External Beam Radiation Therapy
- 手順:Pheresis
- 生物学的:Pneumococcal 13-valent Conjugate Vaccine
- 生物学的:Therapeutic Autologous Dendritic Cells
- 手順:Esophagogastroduodenoscopy
詳細な説明
PRIMARY OBJECTIVE:
I. Evaluation of safety and tolerability of an autologous dendritic cell (DC) vaccine delivered by intra-tumoral injection in patients with primary liver cancer treated with high-dose conformal external beam radiotherapy (EBRT). (Pilot Study) II. Estimate the progression-free survival rate at 2 years post-registration to see if treatment is efficacious compared to historical data in hepatocellular carcinoma (HCC). (Phase II Group 2) II. Estimate the progression-free survival to see if treatment is efficacious compared to historical data in intrahepatic cholangiocarcinoma (iCCA) patients. (Phase II Group 3)
SECONDARY OBJECTIVES:
I. To assess feasibility in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 versus [vs.] 2 vs. 3).
II. To assess overall response rate in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).
III. To assess progression free survival in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).
IV. To assess clinical benefit rate in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).
V. To assess time to response in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).
VI. To assess duration of response in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).
VII. To assess overall survival in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).
RADIOLOGIC STUDY OBJECTIVE:
I. To assess the radiologic response over time of primary liver tumors treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).
CORRELATIVE RESEARCH OBJECTIVES:
I. To monitor patients' immune response after vaccine therapy by group (Group 1 vs. 2 vs. 3).
II. To assess the immune response to pneumococcal 13-valent conjugate vaccine (Prevnar) and similar pneumococcal vaccines by group (Group 1 vs. 2 vs. 3).
OUTLINE:
PILOT STUDY (GROUP I) (CLOSED WITH AMENDMENT 3): Patients with unresectable intrahepatic cholangiocarcinoma (CCA) undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells intratumorally (IT) on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine intramuscularly (IM) on day 1 of cycles 2-4 only. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
PHASE II STUDY (GROUP II): Patients with unresectable HCC undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine or other pneumococcal vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care atezolizumab intravenously (IV) over 30-60 minutes and bevacizumab IV over 30-90 minutes starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo an esophagogastroduodenoscopy (EGD) at screening and CT, PET/CT and/or MRI, biopsy and urine and blood sample collection throughout the study.
PHASE II STUDY (GROUP III): Patients with iCCA undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine or other pneumococcal vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care atezolizumab IV over 30-60 minutes and durvalumab IV starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT, PET/CT and/or MRI, biopsy and urine and blood sample collection throughout the study.
After completion of study treatment, patients are followed up at 2 weeks and then every 3 months for 1 year (beginning at week 36 or 12 weeks after last autologous dendritic cell dose whichever is earlier). Patients are then followed every 3 months until disease progression, and then every 6 months until 5 years after registration.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Clinical Trials Referral Office
- 電話番号:855-776-0015
- メール:mayocliniccancerstudies@mayo.edu
研究場所
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic in Rochester
-
コンタクト:
- Clinical Trials Referral Office
- 電話番号:855-776-0015
- メール:mayocliniccancerstudies@mayo.edu
-
主任研究者:
- Lewis R. Roberts, MD, PhD
-
主任研究者:
- Lionel Kankeu Fonkoua, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Age >= 18 years
-
Pilot study (group 1): Histologic confirmation of intrahepatic CCA (Closed as of amendment 3)
-
Phase II study (group 2): Histologic and/or radiologic confirmation of hepatocellular carcinoma (HCC)
-
Phase II study (group 3): Histologic confirmation of intrahepatic cholangiocarcinoma (iCCA)
-
The following tumor characteristics must be met
-
Unresectable disease: HCC (group 2) or intrahepatic CCA (group 3)
-
Measurable or evaluable disease
-
All lesions should be treatable by EBRT while meeting normal tissue constraints
-
Tumor lesions should be accessible using an ultrasound (US)-guided approach for intratumoral DC injection
-
No evidence of extrahepatic tumor (excluding tumor thrombus) by computed tomography (CT) or magnetic resonance imaging (MRI) scan
- NOTE: Patients who are not candidates for surgical treatment or for ablation with curative intent are allowed
-
-
Good candidate for standard of care high-dose conformal EBRT in the view of the investigator
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
-
GROUP 2 HCC ONLY: Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 15 days prior to registration)
-
GROUP 2 HCC ONLY: Absolute lymphocyte count (ALC) >= 500/mm^3 (obtained =< 15 days prior to registration)
-
GROUP 2 HCC ONLY: Absolute monocyte count (AMC) >= 300/mm^3 (obtained =< 15 days prior to registration)
-
GROUP 2 HCC ONLY: Platelet count >= 50,000/mm^3 (obtained =< 15 days prior to registration)
-
GROUP 2 HCC ONLY: Hemoglobin >= 9.0 g/dL (obtained =< 15 days prior to registration)
-
GROUP 2 HCC ONLY: Total bilirubin < 1.5 mg/dL (obtained =< 15 days prior to registration)
-
GROUP 2 HCC ONLY: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN) (obtained =< 15 days prior to registration)
-
GROUP 2 HCC ONLY: Creatinine =< 2 mg/dL (obtained =< 15 days prior to registration)
-
GROUP 2 HCC ONLY: Prothrombin time (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) =< 1.5 x ULN (obtained =< 15 days prior to registration)
-
GROUP 2 HCC ONLY: Absence of proteinuria at screening as demonstrated by one of the following:
- Urine protein/creatinine (UPC) ratio < 1.0 at screening OR
- Urine dipstick for proteinuria < 2+ (patients discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate =<1g of protein in 24 hours to be eligible)
-
GROUP 3 iCCA ONLY: Absolute neutrophil count (ANC) ≥ 1000/mm^3 (obtained =< 15 days prior to registration)
-
GROUP 3 iCCA ONLY: Absolute lymphocyte count ≥ 500/mm^3 (obtained =< 15 days prior to registration)
-
GROUP 3 iCCA ONLY: Absolute monocyte count ≥ 300/mm^3 (obtained =< 15 days prior to registration)
-
GROUP 3 iCCA ONLY: Platelet count ≥ 50,000/mm^3 (obtained =< 15 days prior to registration)
-
GROUP 3 iCCA ONLY: Hemoglobin ≥ 9.0 g/dL (obtained =< 15 days prior to registration)
-
GROUP 3 iCCA ONLY: Total bilirubin < 1.5 x ULN (obtained =< 15 days prior to registration)
-
GROUP 3 iCCA ONLY: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤ 2.5 x ULN (obtained =< 15 days prior to registration)
-
GROUP 3 iCCA ONLY: Creatinine ≤ 2 mg/dL (obtained =< 15 days prior to registration)
-
GROUP 3 iCCA ONLY: PT/INR/aPTT ≤ 1.5 x ULN (obtained =< 15 days prior to registration)
- NOTE: If patient is receiving therapeutic anticoagulation, patient must be on a stable anticoagulant regimen
-
Ability to provide written consent
-
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
-
Willingness to provide blood and tissue samples for correlative research purposes
Exclusion Criteria:
-
Any of the following because this study involves an investigational agent, the genotoxic, mutagenic and teratogenic effects of which on the developing fetus and newborn are unknown:
- Pregnant persons
- Nursing persons
- Persons of childbearing potential who are unwilling to employ highly effective contraception during heterosexual intercourse while on this study and for 5 months after the last dose of study medication
-
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
-
Immunocompromised patients and patients known to be HIV positive.
- NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial if they are stable on anti-retroviral therapy, have a CD4+ T cell count ≥ 200/uL, and have an undetectable viral load
-
Uncontrolled intercurrent illness including, but not limited to:
- Ongoing or active infection requiring systemic treatment or that could impact patient safety
- Severe infection ≤ 4 weeks prior to registration, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
- Significant cardiovascular disease (New York Heart Association [NYHA] class II), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia
- Or, psychiatric illness/social situations (e.g., substance abuse) that would limit compliance with study requirements
-
Receiving any other investigational agent that would be considered a treatment for the primary neoplasm
-
Other active malignancy =< 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes
-
Major surgery =< 4 weeks prior to enrollment (other than diagnostic surgery or surgical spacer placement in preparation for radiation treatment), or anticipation of need for a major surgical procedure during the study
-
History of hypersensitivity or anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid
-
Active or history of autoimmune disease or immune deficiency, including but not limited to,myasthenia gravis, myositis, autoimmune hepatitis, Crohn's disease, inflammatory bowel disease, antiphospholipid antibody syndrome, rheumatoid arthritis, Sjogren syndrome, systemic lupus erythematosus, Guillain-Barre syndrome, multiple sclerosis, Wegener granulomatosis, or similar conditions
-
NOTE: Exceptions are allowed for:
-
Patients with hypothyroidism on thyroid replacement therapy
-
Patients with type 1 diabetes mellitus on insulin regimen
-
Patients with eczema, psoriasis lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of the following conditions are met:
- Rash must cover < 10% of body surface area
- Disease is well controlled at baseline and requires only low-potency topical corticosteroids
- There has been no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids ≤ 12 months prior to registration
-
-
-
Requires anticoagulant treatment (INR > 1.5 x ULN) or use of anti-platelet agents that cannot be discontinued for the intratumoral injection procedure
- NOTE: Heparin for line patency without detectable lab abnormalities in coagulation will be allowed
-
Corticosteroids =< 2 weeks prior to registration, including oral, intravenous (IV), subcutaneous, or inhaled routes of administration
-
NOTE: Patients on chronic corticosteroids for adrenal insufficiency or other reasons may enroll if they receive less than 10 mg/day of prednisone (or equivalent)
-
NOTE: Exception allowed for patients who need prophylactic steroids prior to imaging for contrast allergies
- Exception: Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study
- Exception: Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study
-
-
History of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
-
Child Pugh class B or C cirrhosis of the liver
-
Previously received immune modulating therapies including but not limited to immune checkpoint inhibitors targeting PD-1 PDL-1 CTLA4, etc.; or prior dendritic cell therapy
-
Prior liver radiation, including radioembolization
-
GROUP 2 ONLY: Barcelona Clinic Liver Cancer (BCLC) stage D disease
-
GROUP 2 ONLY: History of untreated high-risk gastroesophageal varices
-
Active tuberculosis
-
Treatment with therapeutic oral or IV antibiotics ≤ 2 weeks prior to registration
- NOTE: Exception for patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study
-
Prior allogeneic stem cell or solid organ transplantation
-
Treatment with a live, attenuated vaccine ≤ 4 weeks prior to registration
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Phase II Group 2 (EBRT, dendritic cells, Prevnar, atezo, bev)
Patients with unresectable HCC undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine or other pneumococcal vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo an EGD at screening and CT, PET/CT and/or MRI, biopsy and urine and blood sample collection throughout the study. |
Given IV
他の名前:
Undergo MRI
他の名前:
Undergo biopsy
他の名前:
Undergo CT or PET/CT
他の名前:
Undergo PET/CT
他の名前:
Given IV
他の名前:
Undergo urine and blood sample collection
他の名前:
Undergo high-dose EBRT
他の名前:
Undergo apheresis
他の名前:
Given IM
他の名前:
Given IT Undergo EGD
他の名前:
|
|
実験的:Pilot study (pheresis, EBRT, dendritic cells, Prevnar)
Patients with unresectable intrahepatic CCA undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine IM on day 1 of cycles 2-4 only. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. (CLOSED WITH AMENDMENT 3) |
Undergo high-dose EBRT
他の名前:
Undergo apheresis
他の名前:
Given IM
他の名前:
Given IT |
|
実験的:Phase II Group 3 (EBRT, dendritic cells, Prevnar, atezo, tir)
Patients with iCCA undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine or other pneumococcal vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care durvalumab IV starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT, PET/CT and/or MRI, biopsy and urine and blood sample collection throughout the study. |
Undergo MRI
他の名前:
Undergo biopsy
他の名前:
Undergo CT or PET/CT
他の名前:
Undergo PET/CT
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Undergo urine and blood sample collection
他の名前:
Undergo high-dose EBRT
他の名前:
Undergo apheresis
他の名前:
Given IM
他の名前:
Given IT |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of significant toxicity (Pilot study)
時間枠:Up to completion of cycle 2 (each cycle is 28 days)
|
A significant toxicity is defined as a dose limiting toxicity that is possibly, probably, or definitely related to dendritic cell (DC) treatment. Toxicities will be assessed using the Cancer Therapy Evaluation Program active version of the Common Terminology Criteria for Adverse Events. |
Up to completion of cycle 2 (each cycle is 28 days)
|
|
Progression-free survival rate at 2 years (Phase II)
時間枠:At 2 years
|
Defined as the time from registration to disease progression or death due to all causes. |
At 2 years
|
|
PFS (Phase II Group 3)
時間枠:Up to 5 years
|
Defined as the time from registration to disease progression or death due to all causes. |
Up to 5 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall response rate
時間枠:Up to 1 year post treatment
|
The overall response rate will be estimated by the number of patients with an objective status of complete response (CR) or partial response (PR) divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true overall response rate will be calculated. |
Up to 1 year post treatment
|
|
Number of patients who received at least one dose of intratumoral DC injection
時間枠:Up to 1 year post treatment
|
The feasibility of the regimen will be estimated by the number of patients who received at least one dose of intratumoral DC injection divided by the total number of patients who received apheresis. |
Up to 1 year post treatment
|
|
Clinical benefit rate
時間枠:Up to 1 year post treatment
|
The clinical benefit rate will be estimated by the number of patients with an objective status of stable disease or CR or PR at any time divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true clinical benefit rate will be calculate |
Up to 1 year post treatment
|
|
Time to response
時間枠:Up to 1 year post treatment
|
Time to response is defined for all evaluable patients who have achieved an objective response as the date of initiation of vaccination treatment to the date at which the patient's objective status is first noted to be either a CR or PR. Time to response will be summarized descriptively using Kaplan-Meier methodology. |
Up to 1 year post treatment
|
|
Duration of response
時間枠:Up to 1 year post treatment
|
Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the earliest date progression is documented. Duration of response will be summarized descriptively using Kaplan-Meier methodology. |
Up to 1 year post treatment
|
|
Overall survival
時間枠:Up to 5 years
|
Defined as the time from registration to death from any cause. |
Up to 5 years
|
|
Progression-free survival
時間枠:Up to 5 years
|
Defined as the time from registration to disease progression or death due to all causes. |
Up to 5 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in target lesion measurements
時間枠:Baseline up to 1 year post treatment
|
All enhancing lesions will be evaluated over time for each patient. The percent change from baseline in target lesion measurements will be assessed over time. Differences in values over time will be summarized descriptively and graphically. |
Baseline up to 1 year post treatment
|
|
Change in immunologic correlates before and after vaccination treatment
時間枠:Baseline up to 1 year post treatment
|
Change in immunologic correlates before and after vaccination treatment will be evaluated and summarized both quantitatively and graphically. Each of the correlative endpoints will be summarized individually, but will also be evaluated in terms of their relationships to one another; i.e., will use Spearman rank correlation coefficient to assess the correlations between baseline levels as well as between changes before and after treatment in these immunologic markers. In addition, these immunologic markers will be correlated with cancer and treatment related outcomes (e.g. response, adverse events). Relationships will also be explored graphically using scatter plots. |
Baseline up to 1 year post treatment
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Lewis R. Roberts, MD, PhD、Mayo Clinic in Rochester
- 主任研究者:Lionel Kankeu Fonkoua, MD、Mayo Clinic in Rochester
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 部位別新生物
- 新生物
- 組織型別の新生物
- 消化器系腫瘍
- 消化器系疾患
- 肝疾患
- 新生物、腺および上皮
- 腺癌
- 肝腫瘍
- がん
- がん、肝細胞
- 胆管癌
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 硫黄化合物
- 有機化学物質
- 調査手法
- 治療
- 臨床検査技術
- 診断技術と手順
- 診断
- 外科的処置、手術
- 低侵襲外科的処置
- 細胞学的技術
- 細胞診断
- 物理現象
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 無機化学物質
- 組織
- ヘルスケアの経済学と組織
- 診断技術、外科的
- 内視鏡検査、胃腸
- 診断技術、消化器系
- 内視鏡検査
- 消化器系の外科的処置
- 化学技術、分析
- スペクトル分析
- 免疫グロブリンアイソタイプ
- 硫化物
- 陰イオン
- イオン
- 電解質
- 硫化水素
- ベバシズマブ
- 免疫グロブリンG
- 放射線
- トピックとしての議会
- 生検
- 標本処理
- 磁気共鳴分光法
- Durvalumab
- ジスルフィド
- アテゾリズマブ
- 内視鏡検査、消化器系
- 血液成分の除去
- 胃鏡検査
- 13バレント肺炎球菌ワクチン
その他の研究ID番号
- MC1641
- R01CA274985 (米国 NIH グラント/契約)
- 16-009335 (その他の識別子:Mayo Clinic Institutional Review Board)
- R01CA294704 (米国 NIH グラント/契約)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。